Pediatric radiology · 2025
Comparison of phase-resolved functional lung (PREFUL) and hyperpolarized 129Xe MRI for longitudinal monitoring of lung function in pediatric cystic fibrosis following elexacaftor/tezacaftor/ivacaftor.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Munidasa Samal, Alam Faiyza, Zanette Brandon, Li Daniel, Wee Wallace, Braganza Sharon, Woods Jason, Ratjen Felix, Santyr Giles
Аннотация
BACKGROUND: Phase-resolved functional lung (PREFUL) MRI offers a more accessible alternative to hyperpolarized 129Xe MRI (Xe-MRI) for monitoring treatment response in pediatric cystic fibrosis (CF), but longitudinal comparisons are limited.
OBJECTIVE: To assess longitudinal lung function changes following elexacaftor/tezacaftor/ivacaftor (ETI) treatment initiation in CF children using PREFUL MRI, in comparison with Xe-MRI and pulmonary function tests (PFTs).
MATERIALS AND METHODS: PREFUL MRI, Xe-MRI, and PFTs were performed in 14 CF patients (median [IQR] age 15 [14-16.5] years old) at baseline and 1 month, 6 months, 12 months, and 24 months following initiation of ETI treatment. Ventilation and defect percentage (VDP) was derived from PREFUL MRI (regional ventilation VDP, VDPRVent; regional-flow volume loop cross-correlation VDP, VDPCC; and the combination of VDPRVent and VDPCC, VDPcombined) and Xe-MRI (VDPXe) maps. Perfusion defect percentage (QDP) was derived from normalized perfusion maps and, with VDPcombined, determined the percentage of healthy ventilation-perfusion matching (VQM). Significance of 1-month treatment changes was determined using the Wilcoxon-signed rank test and was correlated between metrics using Spearman ranked correlation.
RESULTS: All PREFUL measures significantly improved (P < 0.01) 1-month post-treatment in agreement with changes in Xe-MRI VDP and PFTs (P < 0.03). The absolute change in VDPCC and VDPcombined significantly correlated with VDPXe (r ≥ 0.62, P < 0.02), unlike VDPRVent (P = 0.35). The change in QDP did not correlate with any metric (P > 0.10). PREFUL MRI and Xe-MRI measures showed minimal changes 1 to 24 months post-treatment (median changes = -2.3% to 1.4%), in agreement with PFTs.
CONCLUSION: PREFUL MRI detects longitudinal treatment-related changes in pulmonary ventilation and perfusion in CF children post ETI.
OBJECTIVE: To assess longitudinal lung function changes following elexacaftor/tezacaftor/ivacaftor (ETI) treatment initiation in CF children using PREFUL MRI, in comparison with Xe-MRI and pulmonary function tests (PFTs).
MATERIALS AND METHODS: PREFUL MRI, Xe-MRI, and PFTs were performed in 14 CF patients (median [IQR] age 15 [14-16.5] years old) at baseline and 1 month, 6 months, 12 months, and 24 months following initiation of ETI treatment. Ventilation and defect percentage (VDP) was derived from PREFUL MRI (regional ventilation VDP, VDPRVent; regional-flow volume loop cross-correlation VDP, VDPCC; and the combination of VDPRVent and VDPCC, VDPcombined) and Xe-MRI (VDPXe) maps. Perfusion defect percentage (QDP) was derived from normalized perfusion maps and, with VDPcombined, determined the percentage of healthy ventilation-perfusion matching (VQM). Significance of 1-month treatment changes was determined using the Wilcoxon-signed rank test and was correlated between metrics using Spearman ranked correlation.
RESULTS: All PREFUL measures significantly improved (P < 0.01) 1-month post-treatment in agreement with changes in Xe-MRI VDP and PFTs (P < 0.03). The absolute change in VDPCC and VDPcombined significantly correlated with VDPXe (r ≥ 0.62, P < 0.02), unlike VDPRVent (P = 0.35). The change in QDP did not correlate with any metric (P > 0.10). PREFUL MRI and Xe-MRI measures showed minimal changes 1 to 24 months post-treatment (median changes = -2.3% to 1.4%), in agreement with PFTs.
CONCLUSION: PREFUL MRI detects longitudinal treatment-related changes in pulmonary ventilation and perfusion in CF children post ETI.